{"id":"NCT03565211","sponsor":"Ferring Pharmaceuticals","briefTitle":"Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures","officialTitle":"A Prospective, Multi-Center, Non-Comparative Trial of the Clinical Safety of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology (ART) Procedures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-26","primaryCompletion":"2019-07-29","completion":"2019-07-29","firstPosted":"2018-06-21","resultsPosted":"2020-11-23","lastUpdate":"2020-11-23"},"enrollment":352,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Progesterone Supplementation in Women Undergoing ART"],"interventions":[{"type":"DRUG","name":"Progesterone vaginal ring","otherNames":[]}],"arms":[{"label":"Progesterone vaginal ring (PVR)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the safety of Progesterone Vaginal Ring (PVR) in women undergoing fresh embryo transfer (ART).","primaryOutcome":{"measure":"Cumulative Rate of Spontaneous Abortions Occurring on or Before 12 Weeks Post-oocyte Retrieval","timeFrame":"On or before 12 weeks post-oocyte retrieval","effectByArm":[{"arm":"Progesterone Vaginal Ring","deltaMin":7.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":254},"commonTop":["Biochemical pregnancy","Nausea","Abortion spontaneous","Headache"]}}